- Aptar Pharma announces the next phase of its global capacity expansion plan in North America, at its Aptar Congers, New York site.
- The expansion includes increased production for proprietary drug delivery systems, initiating Bag-on-Valve (BOV) assembly in the US, and expanding Child-Resistant Senior-Friendly (CRSF) solution production.
- The new capacity is planned to be completed by the end of 2024, significantly boosting capacity across several Aptar Pharma product lines.
Aptar Pharma has shared its plans for the next stage of increasing its production capacity worldwide. The expansion is taking place in North America, specifically at its Aptar Congers, New York site. This strategic move is aimed at meeting the growing prescription and consumer healthcare customer demand for proprietary drug delivery systems.
The expansion includes increased production for proprietary drug delivery systems, including the Unidose (UDS) Nasal Delivery Platform. To support increasing patient demand for systemic nasal delivery, Aptar Pharma is significantly expanding the manufacturing capacity of its proprietary Unidose (UDS) Nasal Spray Systems. The additional capacity is planned to come online in Q4 2024.
Aptar is initiating Bag-on-Valve (BOV) assembly in the United States. to meet increased customer demand in the region for nasal saline solutions. This includes the installation of an assembly line at the Aptar Congers facility to further expand manufacturing of its bag-on-vale (BOV) technology. This new environmentally controlled good manufacturing practice (GMP) production area is planned to be fully operational by early 2025.
As demand continues to grow in North America for child-resistant packaging for nasal decongestant sprays, Aptar Pharma’s plans include a cleanroom extension at the Aptar Congers site for its Child-Resistant Senior-Friendly (CRSF) closure solutions. By the end of 2024 the extension is expected to add an additional 28,500 sq. ft. of manufacturing footprint to enhance warehousing, cleanroom and manufacturing capabilities at the site.
Aptar Pharma’s overall global expansion plan includes an injectables expansion program in France, and new manufacturing facilities in Suzhou, China and Mumbai, India
Overview of outsourcing trends 
